<DOC>
	<DOC>NCT00323297</DOC>
	<brief_summary>To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.</brief_summary>
	<brief_title>Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Subjects aged 18 and over above with PAH and for which bosentan therapy is indicated according to national license Subjects with a mean pulmonary artery pressure of &gt;25mmHg and a pulmonary artery wedge pressure of &lt;15mmHg at rest via right heart catheterization within 3 years prior to randomization. Subjects whose baseline 6 Minute Walk Test distance is &gt;100m and &lt; 450m. PAH secondary to any aetiology including congenital heart disease other than those specified in the inclusion criteria Subjects whose 6 Minute Walk Test may be limited by conditions other than PAH related dyspnoea or fatigue eg. claudication from vascular insufficiency or arthritis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>